Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients-Reference-Cited by-同舟云学术

Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients

Published:2022-07-08 Issue:14 Volume:36 Page:1941-1947
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Micán Rafael,de Gea Grela Alejandro,Cadiñanos Julen,de Miguel Rosa,Busca Carmen,Bernardino Jose I.,Valencia Eulalia,Montes Maria Luisa,Montejano Rocío,Moreno Victoria,Pérez Valero Ignacio,Serrano Lucía,González-García Juan,Arribas Jose R.,Martín-Carbonero Luz

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference18 articles.

1. Bictegravir in a fixed-dose tablet with emtricitabine and tenofovir alafenamide for the treatment of HIV infection: pharmacology and clinical implications;Pham;Expert Opin Pharmacother,2019

2. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, noninferiority trial;Daar;Lancet HIV,2018

3. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, noninferiority trial;Molina;Lancet HIV,2018

4. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) in virologically suppressed HIV-1 infected women: a randomized, open-label, multicenter, active-controlled, phase 3, noninferiority trial;Kityo;J Acquir Immune Defic Syndr,2019

5. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184 V/I;Andreatta;J Antimicrob Chemother,2019

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The RT M184V resistance mutation clearance in the reservoir is mainly related to CD4 nadir and viral load zenith independently of therapeutic regimen type;Journal of Antimicrobial Chemotherapy;2024-05-28

2. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis;Journal of Antimicrobial Chemotherapy;2024-05-17

3. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV from the Canadian cohort of the observational BICSTaR study;Medicine;2024-04-19

4. Twelve‐month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real‐world insights from BICSTaR cohorts;HIV Medicine;2023-12-26

5. Bictegravir/Emtricitabine/Tenofovir Alafenamide for HIV-1: What is the Hidden Potential of This Emerging Treatment?;HIV/AIDS - Research and Palliative Care;2023-11